Finch Therapeutics Group, Inc. Overview
Pro stress-test →Finch Therapeutics is an early pioneer in microbiome therapeutics with a leading portfolio of innovative microbiome assets with potential applicability across a wide range of therapeutic areas. The company develops microbiome candidates including FIN-211 for autism spectrum disorder symptoms, FIN-524 for ulcerative colitis, and FIN-525 for Crohn's disease. However, on March 22, 2026, Finch Therapeutics Group filed a voluntary petition for reorganization under Chapter 11, significantly impacting its strategic position.
Strategic Profile
Pro stress-test →Finch has a robust intellectual property estate including more than 70 issued U.S. and foreign patents with critical relevance for both donor-derived and donor-independent microbiome therapeutics. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota. The company is currently focused on navigating restructuring while preserving its valuable IP portfolio and therapeutic assets.
Competitive Landscape
Pro stress-test →The microbiome therapeutics space includes players like Seres Therapeutics (SynsporeticTM technology), Gilead Sciences (microbiome programs), and OpenBiome (fecal microbiota repository). Finch competes through proprietary donor-derived and donor-independent microbiome composition strategies. The market remains nascent with significant regulatory uncertainty, giving established microbiome pioneers a competitive advantage despite the current financial distress.
Industry Context
Finch Therapeutics Group, Inc. operates in Microbiome therapeutics.
Key facts
Founded: 2014 · Headquarters: Boston, United States · Employees: N/A · Revenue: N/A · Market cap: $11.96M